Clinical Trials

For some patients, clinical trials offer a source of hope that a new treatment will provide the medical intervention they need to win their battle against cancer. These treatment trials also provide the critical research necessary to continue the search for a cure.

Cancer patients treated in well-organized clinical trials, in general, do as well or better than patients receiving "standard" treatments, particularly in difficult cancers where traditional treatments have not had a high success rate.

Experiencing tremendous growth since its establishment, the Penn State Hershey Cancer Institute at Mount Nittany Medical Center continues to participate in clinical research.

Contact Information

Please direct any questions to a Penn State Hershey Cancer Institute trials office staff member:


A Randomized, Phase III Trial of Endocrine Therapy plus Etinostat/Placebo in Men and Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer. E2112 Clinical Abstract (PDF)
Phase III Randomized Placebo Controlled Clinical Trial Evaluting the use of Adjuvent Endocrine Therapy +/- One Year of Everolimus in Patients with High Risk Hormone Receptor Positive and Her2 Negative Breast CancerTrial of Endocrine Therapy plus Etinostat/Placebo in Men and Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer. S1207 Clinical Abstract (PDF)
A Randomized Phase III Trial of Adjuvent Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer. NRG-BR003 Clinical Abstract (PDF)


An International Multicentre Open Label Randomized Phase II Advanced Anal Cancer Trial Comparing Clsplatin plus-5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease. EA2133 Clinical Abstract (PDF)


JoLT-Ca STABLE-MATES Trial (STU 022015-069):
A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC). JoLT-Ca STABLE-MATES Trial (STU 022015-069) Clinical Abstract (PDF)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). A151216 Clinical Abstract (PDF)
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Recptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). A081105 Clinical Abstract (PDF)
A Phase III Double-Blind Trial for Surgically Resected Early State Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (An Alchemist Treatment Trial). E4512 Clinical Abstract (PDF)


There are no trials at this time.


Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma. E1412 Clinical Abstract (PDF)

Multiple Myeloma

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma. E3A06 Clinical Abstract (PDF)


There are no trials at this time.

Head & Neck

There are no trials at this time.


A Randomized Phase II Trial of Ipilumumab with or Without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma. E3612 Clinical Abstract (PDF)


There are no trials at this time. 


There are no trials at this time.


There are no trials at this time.

Barbara Gutch, RN, OCN
Clinical Research Coordinator
Phone: 814.231.7843
Fax: 814.231.7039

Shannon Fisher, RN
Clinical Research Coordinator
Phone: 814.231.7813
Fax: 814.231.7039

Amy Long, BS, CCRP
Data Manager
Phone: 814.231.7810
Fax: 814.231.7039